Press Releases

Date Title and Summary
Toggle Summary Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
MADISON, Wis. , Feb. 5, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the BTIG MedTech, Digital Health , Life Science & Diagnostic Tools Conference , which takes place on February 13, 2024 .     BTIG-hosted events are intended for prospective and
Toggle Summary Accuray Reports Fiscal 2024 Second Quarter Financial Results
19% Order Growth YOY; 8% Service Revenue Expansion; Confirms FY24 Guidance MADISON, Wis. , Jan. 31, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter and six-months ended December 31, 2023 .
Toggle Summary Providence Swedish Radiosurgery Center in Seattle Invests in Second Accuray CyberKnife® System, a Robotic Delivery Device That Makes Extremely Precise Radiation Treatments Possible in 1-5 Sessions
New System Will Play a Key Role in Delivering Radiation Treatments in One of the Largest Cancer Facilities in Washington State MADISON, Wis. , Jan. 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Providence Swedish Radiosurgery Center in Seattle, Washington is
Toggle Summary Accuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024
MADISON, Wis. , Jan. 16, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023 , during a conference call hosted by company management at 1:30 p.m. PT / 4:30 p.m. ET on January 31, 2024 .
Toggle Summary Accuray Initiates Sales of the VitalHold™ Solution in Japan, Supporting Surface-guided Radiation Therapy on the Radixact® System
MADISON, Wis. , Dec. 5, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation therapy (SGRT) on the Radixact ® System in Japan beginning November 30, 2023 .
Toggle Summary Accuray Reports Fiscal 2024 First Quarter Financial Results
Company Achieves 8% Revenue Growth, Reiterates FY 2024 Guidance MADISON, Wis. , Nov. 7, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2024 ended September 30, 2023 .     First Quarter Fiscal 2024 Summary Net revenue of
Toggle Summary Accuray to Participate in the 14th Annual Jefferies London Healthcare Conference
MADISON, Wis. , Oct. 31, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the 14 th Annual Jefferies London Healthcare Conference. The management team is scheduled to participate in a presentation with moderated Q&A on Wednesday, November 15 th , 2023 at
Toggle Summary Accuray to Report First Quarter Fiscal 2024 Financial Results on November 7, 2023
MADISON, Wis. , Oct. 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2024, ended September 30, 2023 , during a conference call hosted by company management at 1:30 p.m. PT / 4:30 p.m. ET on November 7, 2023 .
Toggle Summary Accuray Announces Approval of the Tomo® C Radiation Treatment Delivery System by China's National Medical Products Administration
MADISON, Wis. , Oct. 3, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo ® C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration (NMPA).
Toggle Summary Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting
MADISON, Wis. , Oct. 2, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has a 510(k) pending for an online adaptive therapy option*, Cenos™, for its Radixact ® System. The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO ( American

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.